$VZ

5 Safe High-Yield Stocks Boomers Should Own in August

The article highlights five US-listed dividend stocks and says each recently raised or reaffirmed full-year guidance, emphasizing free-cash-flow coverage over headline yield. It cites Verizon (VZ) Q2 2026 EPS and raised FY26 guidance, Altria (MO) raised FY26 EPS guidance, Enterprise Products Partners (EPD) higher distribution and payout ratio, Realty Income (O) raised AFFO guidance, and Amgen (AMGN) raised FY26 guidance and Q2 cash flow.

Original reporting
Published Aug 16, 2026, 12:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 16, 2026, 12:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
5 Safe High-Yield Stocks Boomers Should Own in August — source image
Decision brief

The 30-second read

$VZBullishLow
01

Why it matters

The text provides company-specific guidance ranges and operating metrics for five dividend payers, but it does not present a single new breaking event beyond what is implied to have been reported “last quarter.”

02

Market read

Useful for income-screening and relative risk framing, but it is not a fresh catalyst-driven trading call.

03

What to watch

For MO and EPD, commodity and volume/transition execution risks could dominate; for O, non-investment-grade tenant exposure could matter more than occupancy alone; for AMGN, biosimilar pressure on Prolia may worsen before pipeline offsets.

Relevance 4/10Novelty 4/10Timing: August 2026 income-screen framing, with AMGN ex-dividend noted for Aug 21.

Background

A promotional-style August 2026 list argues for dividend durability by screening for free-cash-flow coverage and long dividend track records.

Company-level read

Ticker impact

$VZBullishMedium confidence
Context

Verizon raised FY26 adjusted EPS guidance to $4.99 to $5.04 and cited continued dividend increases, with Q2 FCF up 27.1%.

Expected impact

Modest positive bias for income-focused positioning; upside likely capped by the 2027 deleveraging narrative.

Evidence & confidence

The article provides specific Q2 datapoints (EPS beat, FCF growth) and a concrete FY26 guidance range, but it is framed as a “safe high-yield” list rather than a fresh standalone catalyst.

$MONeutralMedium confidence
Context

Altria raised FY26 adjusted EPS guidance to $5.61 to $5.72, while Q2 adjusted diluted EPS rose 2.8% year over year.

Expected impact

Likely range-bound unless cigarette volume trends stabilize; dividend coverage narrative may cushion downside.

Evidence & confidence

The text includes guidance and Q2 EPS figures, but the core risk (contracting cigarette volumes) is also explicitly reiterated.

$EPDBullishMedium confidence
Context

Enterprise Products Partners increased the Q3 2026 distribution to $0.56 per unit and reported Q2 adjusted EBITDA of $2.8 billion.

Expected impact

Slightly positive for yield-focused flows; volatility risk could limit sustained upside.

Evidence & confidence

The article gives concrete distribution and operating metrics plus a capex guidance increase, which are actionable for assessing coverage.

$OBullishMedium confidence
Context

Realty Income raised full-year AFFO guidance to $4.44 to $4.45 and reported Q2 AFFO per share up 3.8%.

Expected impact

Mild positive bias for REIT income positioning; valuation may be sensitive to any credit deterioration.

Evidence & confidence

The piece includes specific guidance ranges and occupancy, but it is still a promotional roundup rather than a single-company breaking update.

$AMGNNeutralMedium confidence
Context

Amgen raised FY26 guidance to revenue $38.2 to $39.4 billion and non-GAAP EPS $22.30 to $23.50, with Q2 FCF $3.5 billion.

Expected impact

Potentially supportive for holders around the ex-dividend date, but stock reaction likely muted without a new event beyond guidance.

Evidence & confidence

The article provides detailed guidance and cash flow figures, yet the overall framing is a “safe stocks” list, not a new discrete disclosure.

Market effects

Reinforces the income-investing playbook across telecom, tobacco, energy MLPs, REITs, and large-cap biotech, emphasizing free-cash-flow coverage over headline yield.

Primarily US-listed dividend flow narrative; no explicit cross-region macro shock described.

Limited global spillover; only broad commodity and credit-quality sensitivities are mentioned.

Counterpoint

The article’s “safe” framing may underweight valuation and duration risk, since it focuses on payout coverage while not addressing how rates or credit spreads could compress yields.

Key entities

  • Verizon Communications

    Raised FY26 adjusted EPS guidance to $4.99 to $5.04; Q2 FCF rose 27.1%.

  • Altria Group

    Raised FY26 adjusted EPS guidance to $5.61 to $5.72; Q2 adjusted diluted EPS up 2.8%.

  • Enterprise Products Partners

    Increased Q3 2026 distribution to $0.56 per unit; Q2 adjusted EBITDA $2.8B; capex guidance higher.

  • Realty Income

    Raised full-year AFFO guidance to $4.44 to $4.45; Q2 AFFO per share up 3.8%.

  • Amgen

    Raised FY26 revenue and non-GAAP EPS guidance; Q2 free cash flow $3.5B; Prolia sales down 33%.

Related articles

$OMedAI 8/10

Realty Income Announces Closing of $1.0 Billion Convertible Senior Notes Offering

Realty Income (NYSE: O) closed a private offering of $1.0 billion 3.750% convertible senior notes due 2031, including an $875.0 million base and a $125.0 million option. Net proceeds were about $981.9 million. The company paid about $33.2 million for capped call hedges and repurchased about 3.0 million shares for about $188.7 million, using the remainder for general corporate purposes.

$AVACHighAI 9/10

Drug Trial Data Manipulation Wiped Avacopan’s EU Approval as FDA Hearing Looms

The EMA published an Aug 6, 2026 assessment report detailing alleged manipulation of nine patient records in the ADVOCATE Phase 3 trial of avacopan (Tavneos), after database lock and unblinding. The European Commission revoked EU approval Aug 6, 2026, following a June 25 CHMP recommendation. In the US, the FDA is reviewing Amgen’s July 23 hearing submission to withdraw Tavneos, based on similar data-integrity issues.

$AMGNMedAI 8/10

Tavneos trial flagged for 'serious breaches' of protocol as EU regulators dissect market withdrawal decision

EU regulators reversed Tavneos’ marketing authorization after the EMA’s CHMP cited “serious” good clinical practice breaches in the Advocate phase 3 trial, including unblinding and re-adjudication that changed week-52 results. CHMP also flagged serious hepatic safety risks. Tavneos was developed by ChemoCentryx, acquired by Amgen ($3.7B). CSL Vifor holds EU rights; Amgen contests the decision and seeks an FDA hearing.

$AMGNHighAI 8/10

Pressure piles on Amgen after EU pulls Tavneos, flags ‘serious breaches’ in pivotal study

The EU regulator, according to an EMA document, said it revoked Amgen’s Tavneos marketing authorization after finding “serious breaches” in the drug’s pivotal trial, including access to unblinded efficacy data and rerunning primary analysis that changed results. The EU concluded the study was unreliable. Tavneos is also under FDA scrutiny; Amgen requested a hearing.

$VZMedAI 8/10

Why is VZ stock surging today?

Investing.com reports VZ (VZ stock) rose 5.6% after the company released H1 2026 results. VZ said net profit was CHF 131.9 million, up 17.7% YoY, and revenue CHF 316.5 million, up 13.9%. Managed assets revenue rose 18.2% to CHF 216.6 million, net new inflows were about CHF 3.3 billion, and AUM increased to CHF 67.7 billion. The article cites a dividend growth expectation and a UK expansion plan.